Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Ovarian Cancer Metastatic × fludarabine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 13 Precursor Cell Lymphoblastic Leukemia-Lymphoma 7 Leukemia, Lymphocytic, Chronic, B-Cell 7 Hematologic Neoplasms 6 Myelodysplastic Syndromes 5 Leukemia 5 Burkitt Lymphoma 5 Multiple Myeloma 4 Lymphoma, Non-Hodgkin 4 Lymphoma 4 Lymphoma, Mantle-Cell 3 Lymphoma, Follicular 3 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3 Leukemia, Biphenotypic, Acute 3 Breast Neoplasms 3 Stomach Neoplasms 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Pancreatic Neoplasms 2 Neoplasms 2 Neoplasm Metastasis 2 Melanoma 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, B-Cell, Marginal Zone 2 Lymphoma, B-Cell 2 Leukemia, Prolymphocytic 2 Hematologic Diseases 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Hepatocellular 2 Uterine Cervical Neoplasms 1

Interventions

fludarabine 1 aldesleukin 1 Interleukin-2 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04389229 2020-12-16

OVSTAR

Immetacyte Ltd

Phase 1/2 Withdrawn

Ovarian Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡